After 6 cycles of regimens, the skin lesion and lymph node enlargement obtained remission, but relapsed quickly, consistent with the fact that ALK-negative ALCL responds well to doxorubicin-containing chemotherapy, but frequently relapses. This evidence concerns the gene ALK and anaplastic large cell lymphoma.